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Summary  Crimean-Congo  hemorrhagic  fever  (CCHF)  is  a  tick-borne  disease  with
high  mortality.  Many  disorders  can  mimic  CCHF.  It  is  important  to  recognize  the  condi-
tion  and  to  perform  differential  diagnosis  in  endemic  countries.  Twenty-one  children
aged  18  years  or  less  with  a  preliminary  diagnosis  of  CCHF  were  retrospectively
evaluated.  Real-time  PCR  and  a  conﬁrmatory  indirect  immunoﬂuorescence  assay  for
negative  results  were  performed.  The  diagnoses  determined  that  9  patients  had
(42.9%)  CCHF;  7  patients  had  (33.3%)  viral  upper  respiratory  tract  infections  (URTI);
2  patients  had  (9.5%)  brucellosis;  1  patients  had  (4.7%)  periodic  fever,  aphthous
stomatitis,  pharyngitis,  and  adenitis  (PFAPA)  syndrome  episode;  1  patient  had  (4.7%)
cerebral  palsy,  diabetes  insipidus,  acute  gastroenteritis,  and  hypernatremic  dehy-
dration;  and  1  patient  had  (4.7%)  cellulitis  after  a  tick  bite.  The  mean  age  of  patients
with  CCHF  was  greater  than  that  of  the  other  patients  (116.1  ±  53.6  vs.  94.1  ±  52.1
months,  p  =  0.02).  Seventeen  (81%)  of  the  children  included  had  a history  of  tick
bites,  2  (9.5%)  had  a  history  of  contact  with  a  patient  with  CCHF,  and  2  (9.5%)  had
no  exposure,  but  were  living  in  an  endemic  region.  Three  patients  had  an  underlying
disorder:  cerebral  palsy  and  diabetes  insipidus,  epilepsy,  or  PFAPA.  All  of  the  chil-
dren  experienced  fever.  Other  frequent  symptoms  were  malaise,  diarrhea,  vomiting,
and  abdominal  pain,  but  none  of  these  differed  statistically  between  the  patient
groups.  CCHF  patients  had  a  longer  mean  duration  of  symptoms  (10.56  ±  1.42  vs.
6.75  ±  3.62  days,  p  =  0.008)  and  a  longer  mean  length  of  hospitalization  (8.00  ±  2.08
vs.  3.58  ±  1.56  days,  p  <  0.001)  than  the  other  patients.  At  laboratory  examination,
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rimean-Congo  hemorrhagic  fever  (CCHF)  is  a tick-
orne, viral  infection  caused  by  Crimean-Congo
emorrhagic  fever  virus  from  the  genus  Nairovirus
n the  family  Bunyaviridae. It is  mainly  transmit-
ed to  humans  either  by  bites  of  several  genera
f ixodid  ticks  or  direct  contact  with  the  blood  or
issues of  viremic  patients  or  livestock  [1]. It  is
n arboviral  disease  widely  distributed  across  the
orld from  southern  Russia  and  the  Black  Sea  region
o southern  Africa  [2]. It  was  ﬁrst  recognized  in
urkey  in  2002,  and  since,  Turkey  has  come  to  rep-
esent a  special  case  in  CCHF  epidemiology  and
s an  ‘‘epicenter’’  of  the  disease  with  more  than
000 conﬁrmed  cases  per  year  [3].  People  living  at
ore than  836.5  m  above  sea  level  and  working  in
griculture  and  animal  husbandry  are  at  signiﬁcant
isk for  CCHF  especially  between  May  and  July  [4].
ost cases  occur  in  the  central  and  eastern  parts  of
urkey. Erzurum  and  the  surrounding  area,  where
his study  was  performed,  is  endemic  for  CCHF  [5].
Crimean-Congo  hemorrhagic  fever  has  a
eported general  mortality  in  Turkey  of  up  to  5%
6].  The  clinical  course  in  children  is  milder  than
hat in  adults.  The  clinical  spectrum  may  extend
o an  unfavorable  severity  including  vascular  leaks,
ulti-organ  failure,  shock,  and  hemorrhagic  dis-
ase. Nevertheless,  a  recent  serosurvey  conducted
n endemic  regions  of  Turkey,  including  Erzurum,
eported that  88%  of  the  study  population  had
reviously experienced  subclinical  infections  [7].
t is  important  to  identify  cases  of  CCHF  quickly
ue to  the  risk  of  outbreak.  Nosocomial  cases  have
een reported  [8,9].  Physicians  should  be  alert  and
areful to  differentiate  other  diseases  that  have
pidemiological,  clinical,  and  laboratory  proper-
ies overlapping  with  CCHF.  The  purpose  of  this
tudy  was  to  emphasize  the  differential  diagnosis
f CCHF  in  children  in  an  endemic  country  and  to
emonstrate  differences  in  clinical  and  laboratory
haracteristics between  CCHF  and  other  clinical
pectra.
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stically  signiﬁcant  lower  leukocyte  and  platelet  counts,
 parameters,  and  greater  AST,  ALT,  LDH,  and  CK  levels
mortality  or  complications  occurred  in  the  study.  Both
TI,  cellulitis,  and  brucellosis,  and  non-infectious  causes
 they  are  not  pathognomonic,  some  indicators,  including
nd  hospitalization,  cytopenia,  elevated  liver  enzymes,
d  coagulation  parameters,  were  found  to  be  in  favor  of
ziz  University  for  Health  Sciences.  Published  by  Elsevier
aterials and methods
his  study  was  carried  out  between  April  01  and
eptember  01,  2015  at  the  Erzurum  Regional  Train-
ng and  Research  Hospital,  which  is  a  referral
enter for  the  eastern  part  of  Turkey.  Patients
ith suspected  CCHF  from  Erzurum,  outlying  dis-
ricts and  neighboring  cities  were  either  admitted
irectly or  referred  from  other  hospitals.  Hospital-
zed children  below  18  years  of  age  and  with  CCHF
uspected  on  the  basis  of  epidemiological,  clinical,
nd laboratory  characteristics  were  evaluated  ret-
ospectively.
Blood samples  were  collected  from  all  patients
n admission,  and  all  patients  were  monitored
ith respiratory  and  droplet  isolation  precautions
ntil the  PCR  results  were  obtained.  Real-time
CR (Qiagen® CCHFV  Viral  RNA  Kit,  Qiagen,
ilden, Germany)  was  carried  out  by  the  local
eference laboratory.  Negative  PCR  results  were
onﬁrmed  with  indirect  immunoﬂuorescence  assay
ests. Isolation  was  maintained  for  children  with
CHF until  discharge.  These  children  were  closely
onitored  (patients  with  thrombocyte  counts
50,000/uL were  transferred  to  isolation  rooms  in
he Anesthesiology  Intensive  Care  Unit)  for  vital
igns and  clinical  ﬁndings.  Investigations  includ-
ng hemogram,  C-reactive  protein,  liver  enzymes
aspartate aminotransferase  [AST],  alanine  amino-
ransferase  [ALT],  gamma  glutamyl  transferase
GGT] and  lactate  dehydrogenase  [LDH]),  creatine
inase (CK),  and  coagulation  parameters  (activated
artial  thromboplastin  time  [aPTT],  prothrombin
ime [PT],  and  INR  international  normalized  ratio
INR]) were  performed  from  the  serum  samples.
Intravenous  hydration  with  appropriate  volume
nd electrolyte  concentrations  for  each  child  was
tarted as  a  standard  treatment  regimen.  A  deﬁni-
ive treatment  plan  was  implemented  following
onﬁrmation of  diagnosis.  Children  with  CCHF
ere hospitalized  until  fever  symptoms  resolved,
dequate oral  intake  was  observed,  and  normal
hrombocyte counts  and  coagulation  parameters
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were  achieved.  Other  patients  were  discharged  as
soon as  CCHF  diagnosis  was  excluded  and  other  indi-
cations for  hospitalization  were  resolved.  The  study
was approved  by  the  local  ethical  committee.
Statistical  analyses  were  performed  using  SPSS
for Windows  version  17.0  (SPSS  Inc.,  Chicago,
IL). Compatibility  of  measurable  variables  with
normal  distributions  was  evaluated  using  the
Kolmogorov—Smirnov  test.  Quantitative  data  were
expressed  as  the  mean  ±  standard  deviation  (SD),
and qualitative  data  were  described  as  num-
bers (%).  Differences  between  patients  diagnosed
with CCHF  and  non-CCHF  patients  were  compared
using Fisher’s  exact  test  for  dichotomous  vari-
ables, the  Student’s  t test  or  the  Mann—Whitney  U
test for  continuous  variables.  Signiﬁcance  was  set
at P <  0.05.
Results
Seventeen  (81%)  of  the  21  patients  had  a  history  of
tick bites,  2  (9.5%)  had  a  history  of  contact  with
CCHF patients,  and  2 (9.5%)  had  no  history  of  expo-
sure but  were  living  in  an  endemic  region.  The
ticks were  mostly  found  (n  =  5,  23.8%)  in  the  axil-
lary region.  Other  regions  included  the  trunk  (n  =  4,
19%), arms  (n  =  4,  19%),  head  (n  = 2,  9.5%),  neck
(n =  1,  4.8%),  and  legs  (n  =  1,  4.8%).  Three  patients
had an  underlying  disorder:  cerebral  palsy  and  dia-
betes insipidus,  epilepsy  or  periodic  fever,  aphthous
stomatitis,  pharyngitis,  and  adenitis  (PFAPA)  syn-
drome.
Nine (42.9%)  patients  were  diagnosed  with  CCHF,
whereas  7  (33.3%)  had  viral  upper  respiratory  tract
infections  (URTIs),  2  patients  (9.5%)  had  brucel-
losis,  1 patient  (4.7%)  had  PFAPA  syndrome  episode,
1 patient  (4.7%)  had  cerebral  palsy,  diabetes
insipidus, acute  gastroenteritis,  and  hypernatremic
dehydration, and  1  patient  (4.7%)  had  cellulitis  fol-
lowing tick  bite.  CCHF  diagnosis  was  made  using
RT-RCR.  No  patients  were  serology  positive.
The mean  age  of  the  CCHF  patients  was
116.1 ±  53.6  months,  and  the  mean  age  of  the
other non-CCHF  patients  was  94.1  ±  52.1  months
(p = 0.02).  All  patients  experienced  fever.  Other
frequent symptoms  were  malaise,  diarrhea  and
vomiting,  and  abdominal  pain  and  none  of
these symptoms  differed  statistically  signiﬁcantly
between the  patient  groups.  Myalgia  was  observed
in 3  CCHF  patients  but  in  none  of  the  non-
CCHF patients  (p  = 0.03).  Three  patients  (2  with
CCHF and  1  with  URTI)  had  spontaneous  epistaxis
and a  received  thrombocyte  suspension.  Physical
examination ﬁndings  revealed  tonsillopharyngitis
in 4 patients  (2  with  CCHF,  2  with  URTI)  and
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etechiae  in  2  patients  (1  with  CCHF,  1  with
RTI). Although  no  atypical  cells  were  observed  in
eripheral blood  smears,  bone  marrow  aspiration
as performed  due  to  persistence  of  thrombo-
ytopenia, and  malignancy  was  excluded  in  1
atient.  Three  patients  with  URTI  had  cervical
icro lymphadenopathy.  No  patients  had  hep-
tosplenomegaly.
Crimean-Congo  hemorrhagic  fever  patients  had
 longer  mean  duration  of  symptoms  (10.56  ±  1.42
s. 6.75  ± 3.62  days,  p = 0.008)  and  a  greater
ean length  of  hospitalization  (8.00  ±  2.08  vs.
.58 ±  1.56  days,  p <  0.001)  than  the  other  patients.
t laboratory  examination,  CCHF  patients  had  sta-
istically signiﬁcant  lower  leukocyte  and  platelet
alues  and  greater  AST,  ALT,  LDH,  and  CK  levels  than
he other  patients  (Table  1).  The  CCHF  patients
ere not  given  any  antiviral  treatment,  including
ibavirin. One  child  with  CCHF  was  given  N-acetyl
ysteine therapy  due  to  a rapid  increase  in  liver
nzymes. Prolonged  bleeding  parameters  (aPTT,
NR, or  PT)  were  observed  in  11  (52.4%)  patients.
hese parameters  were  statistically  higher  in  chil-
ren with  CCHF  than  in  other  children  (Table  1).
resh frozen  plasma  was  used  in  5 (23.8%)  CCHF
atients. One  of  these  children  was  also  given
itamin K  supplementation.  Of  the  other  children
ithout CCHF,  3  received  antibiotic  therapy  and  1
eceived desmopressin  acetate  therapy.  All  patients
n the  study  group  were  discharged  without  compli-
ations.
iscussion
he  differential  diagnosis  of  CCHF  includes  other
iral hemorrhagic  infections,  bacterial  septicemias,
almonellosis,  brucellosis,  rickettsiosis,  leptospiro-
is, borreliosis,  malaria,  Lyme  disease,  brucellosis,
 fever,  hepatitis  viruses,  febrile  neutropenia,  and
itamin B12  deﬁciency  [10]. In  the  present  study,
ll patients  were  suspected  and  received  a prelim-
nary diagnosis  of  CCHF  on  the  basis  of  appropriate
xposure history,  symptoms,  and  initial  laboratory
ndings. Accurate  diagnosis  is  only  possible  after
aboratory  conﬁrmation.  Some  patients  were  even-
ually diagnosed  with  different  clinical  spectra,
uch as  URTI,  PFAPA  episode,  cellulitis,  and  diabetes
nsipidus  together  with  hypernatremic  dehydration.
The mean  age  of  the  children  in  this  study  was
pproximately 9.5  years,  which  is  similar  to  the
ean age  of  another  pediatric  CCHF  patient  popula-ion [11].  The  non-CCHF  patients  were  younger  than
he CCHF  patients,  and  most  were  diagnosed  with
 viral  URTI.  Deﬁnitive  etiological  causes  were  not
nvestigated.  Viral  URTI  infections  may  present  with
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Table  1  Clinical  and  laboratory  evaluation  of  patients  hospitalized  due  to  preliminary  diagnosis  of  Crimean-Congo
hemorrhagic  fever  (CCHF).
CCHF  patients
n  =  9  (42.9%)
Other  patientsa
n  =  12  (57.1%)
p Value
Age  (months)  (mean  ±  SD) 116.1  ±  53.6 94.1  ±  52.1 0.02*
Duration  between  tick  bite  and  start
of  symptoms  (days)  (median
[min—max])
1  [1—5] 2  [1—7] 0.30
Duration  of  symptoms  (days)
(mean  ±  SD)
10.56  ±  1.42  6.75  ±  3.62  0.008*
Duration  of  hospitalization  (days)
(mean  ±  SD)
8.00  ±  2.08  3.58  ±  1.56  <0.001*
Male  sex  n  (%) 8  (%88.9) 10  (%83.3)  0.70
Symptoms
Fever,  n  (%)  9  (100%)  12  (100%)  NS
Malaise,  n  (%)  8  (88.9%)  7  (58.3%)  0.10
Diarrhea  and  vomiting,  n  (%)  7  (77.8%)  5  (41.7%)  0.09
Abdominal  pain,  n  (%) 5  (55.6%)  3  (25.0%)  0.10
Cough,  n  (%) 4 (44.4%) 4  (33.3%)  0.60
Nasal  discharge/obstruction,  n  (%) 3  (37.5%)  5  (41.7%)  0.50
Sore  throat,  n  (%) 3  (33.3%) 1  (8.3%)  0.10
Myalgia,  n  (%) 3  (33.3%) 0  (0%) 0.03*
Bleeding,  n  (%) 2  (22.2%) 1  (8.3%)  0.30
Rash,  n  (%) 1 (11.1%) 1  (8.3%) 0.80
Arthralgia,  n  (%) 0  (0%) 2  (16.7%) 0.20
Laboratory  ﬁndings
Lowest  WBC  value  (/uL)
(median  [min—max])
1905
[1266—4010]
5330
[1400—24,900]
0.02*
Lowest  Hb  value  (g/dL)
(mean  ±  SD)
13.1  ±  1.5  12.6  ±  2.0  0.40
Lowest  platelet  value  (/uL)
(median  [min—max])
66,000
[17,000—1,39,900]
1,57,450
[27,480—4,39,100]
0.02*
Highest  CRP  level  (0—5  mg/dL)
(mean  ±  SD)
2.37  ±  2.36  2.65  ±  2.61  0.70
Highest  AST  level  (5—34  U/L)
(median  [min—max])
256 [120—1138]  40.5  [16—159]  0.001*
Highest  ALT  level  (0—55  U/L)
(median  [min—max])
157 [50—363]  16.5  [9—154]  0.001*
Highest  GGT  level  (12—64  U/L)
(median  [min—max])
34 [15—313]  11.5  [8—84]  0.07
Highest  LDH  level  (125—220  U/L)
(median  [min—max])
520 [341—1679]  352  [200—1007]  0.05*
Highest  CK  level  (30—200  U/L)
(median  [min—max])
390 [109—25,312]  100  [31—1320]  0.03*
Highest  aPTT  level  (21—35  s)
(mean  ±  SD)
34.7  ±  11.0  25.6  ±  2.7  0.007*
Highest  INR  level  (0.8—1.2)
(mean  ±  SD)
1.35  ±  0.17  1.14  ±  0.10  0.01*
Highest  PT  level  (10.5—14.9  s)
(mean  ±  SD)
15.9  ±  2.4  13.8  ±  1.2  0.04*
* All bold values are statistically signiﬁcant.
a Upper respiratory tract infections, brucellosis, PFAPA (periodic fever, aphtous stomatitis, pharyngitis, and adenitis) syndrome
episode, cerebral palsy + diabetes insipidus + acute gastroenteritis + hypernatremic dehydration, cellulitis due to tick bite.
min, minimum; max, maximum; SD, standard deviation; WBC, white blood cell count; Hb, hemoglobin; CRP, C-reactive protein;
AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gama glutamyl transferase; LDH, lactate dehydrogenase;
CK, creatine kinase; aptt, activated partial thromboplastin time; INR, international normalized ratio; PT, prothrombin time.
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conjunctivitis,  coryza,  cough,  diarrhea,  hoarse-
ness,  stomatitis,  and  viral  exanthema,  which  all
resemble  CCHF  [12]. The  laboratory  ﬁndings  of
these infections  may  also  mimic  CCHF.  Worsen-
ing cytopenia  [13,14]  and  prolonged  PT  and  aPTT
as well  as  elevated  serum  LDH,  AST,  ALT,  and  CK
are common  during  the  course  of  viral  respira-
tory infections  [15]. Even  patients  with  URTI  may
exhibit  spontaneous  bleeding,  as  was  observed  in
one thrombocytopenic  patient  in  the  current  study.
By virtue  of  their  being  one  of  the  most  com-
mon admission  diagnoses  in  children,  we  assume
that viral  URTIs  will  continue  to  complicate  the
differential  diagnosis  of  CCHF  in  endemic  regions.
Erzurum  is  also  endemic  for  brucellosis.  This  may
also mimic  CCHF  [16]. Two  patients  were  diagnosed
with brucellosis  in  the  present  study.  Although
brucellosis has  distinct  transmission  routes,  over-
lapping  properties  compatible  with  CCHF  resulted
in these  patients  being  tested  for  CCHF.  Brucellar
clinical polymorphism,  including  fever,  arthralgia,
gastrointestinal  symptoms,  fatigue  and  anorexia,
and  laboratory  characteristics,  such  as  cytopenia,
clotting disorders  and  elevated  LDH,  AST,  and  ALT,
may also  resemble  CCHF  [17—19]. Patients  with
other diagnoses  were  also  initially  considered  to
have a  preliminary  diagnosis  of  CCHF  due  to  fever
and  other  nonspeciﬁc  symptoms  and  compatible
epidemiological  and  laboratory  data.
Crimean  Congo  hemorrhagic  fever  involves  var-
ious clinical  phases:  incubation,  pre-hemorrhagic,
hemorrhagic,  and  convalescence  periods.  The  incu-
bation period  usually  lasts  from  1  to  7  days
depending on  the  virus  titer  and  route  of  trans-
mission [20].  In  this  study,  the  incubation  period
lasted between  1  and  5 days  after  tick  bite  in  CCHF
patients.  No  difference  was  observed  between
CCHF and  non-CCHF  patients  in  terms  of  mean
incubation periods.  All  patients  in  this  study  had
fever, which  is  the  predominant  symptom  of  the
pre-hemorrhagic  period  in  CCHF.  Additionally,  non-
speciﬁc symptoms,  including  malaise,  vomiting,
diarrhea, and  abdominal  pain,  which  were  also
widely  seen  in  our  patients,  are  common  during  the
course of  CCHF  [11,21]. Tonsillopharyngitis,  which
has been  reported  as  common  among  children  with
CCHF [11],  was  present  in  2 cases  of  CCHF  in  this
study,  which  may  also  lead  to  confusion  during  dif-
ferential  diagnosis.  The  hemorrhagic  period  usually
begins between  days  3  and  5 of  the  disease  and
continues for  another  2—3  days  [10]. Petechiae,
hematomas,  and  bleeding  from  various  areas  may
be seen.  Epistaxis,  which  is  one  of  the  most  fre-
quent types  of  bleeding  in  pediatric  subjects,  was
observed  in 2  out  of  9 (22.2%)  patients  in  the
current study  [11,21]. Prolongation  in  coagulation
C
D
lS.S.  Kara  et  al.
arameters  has  previously  been  reported  in  chil-
ren with  CCHF  and  was  similar  in  the  present  study
11,21].
Other laboratory  ﬁndings  of  CCHF  patients  in  this
tudy, such  as  the  low  thrombocyte  and  leukocyte
ounts and  high  AST,  ALT,  LDH,  and  CK  levels,  dif-
ered signiﬁcantly  from  those  of  the  other  patients.
eukopenia,  thrombocytopenia,  prolonged  aPTT,
levated  LDH  and  ALT,  and  the  presence  of  melena
nd somnolence  have  previously  been  reported
s independent  predictors  of  mortality  among
CHF patients  [22,23]. Although  no  mortality  was
bserved  in  the  study  population,  prominent  ﬁnd-
ngs involving  cytopenia,  increased  liver  enzymes
nd CK,  and  prolonged  bleeding  parameters  should
aise suspicion  of  CCHF  in  endemic  countries.
Tasdelen  Fisgin  et  al.  reported  that  two-thirds  of
CHF patients  were  initially  misdiagnosed  because
f nonspeciﬁc  early  signs  and  symptoms  [24].
ery high  subclinical  infection  rates  have  also
een reported  [7]. Although  lower  mortality  has
een documented  in  children  [6,11],  it  is  vitally
mportant  to  diagnose  CCHF  and  isolate  suspected
atients until  diagnosis  due  to  CCHF’s  major  pub-
ic health  consequences.  The  majority  of  our  study
opulation  (81%)  had  a  history  of  tick  bites.  The
urkish  Ministry  of  Health  cites  a ﬁgure  of  approxi-
ately 60%  for  CCHF  patients  [25].
In this  study,  both  the  total  symptomatic  period
nd the  length  of  hospitalization  were  longer  in
CHF patients  than  in  the  other  patients.  This  may
eﬂect the  more  serious  and  longer  clinical  course
f CCHF.  The  mean  duration  of  symptoms  (pre-
emorrhagic and  hemorrhagic)  in  CCHF  patients
as compatible  with  the  time  until  convalescence
3,10]. The  length  of  hospitalization  in  the  CCHF
atients  may  also  reﬂect  time  required  to  recover
rom the  thrombocytopenia  and  prolonged  coagu-
ation parameters.
Deﬁnitive  diagnosis  of  CCHF  is  based  on  labora-
ory conﬁrmation.  Viral  RNA  is  detectable  in  serum
amples  using  RT-PCR  until  the  18th  day  [20].  This
as the  method  used  to  diagnose  CCHF  patients  in
his study.  There  is  no  proven  speciﬁc  treatment
or CCHF,  and  patients  were  not,  therefore,  given
ntiviral  medication.  As  advised  in  the  literature,
he use  of  supportive  treatment  with  i.v.  ﬂuids,  gas-
ric protective  drugs,  thrombocyte  suspension  and
resh frozen  plasma,  if  necessary,  has  been  reported
26,27].onclusions
espite  the  small  sample  size,  this  study  high-
ights the  importance  of  the  differential  diagnosis
C rrha
o
c
b
b
t
i
c
e
s
p
a
i
d
p
o
b
w
F
N
C
N
E
N
R
[
[
[
[
[
[
[
[
[
[
[
[
[
[linical  conditions  mimicking  Crimean-Congo  hemo
f  CCHF.  Our  results  reveal  that  not  only  infectious
auses, such  as  URTI,  cellulitis,  and  brucellosis,
ut also  speciﬁc  non-infectious  causes  may  resem-
le CCHF,  especially  in  endemic  regions.  Although
hey are  not  pathognomonic,  some  laboratory  ﬁnd-
ngs, including  cytopenia,  elevated  liver  enzymes,
reatine kinase,  and  prolonged  coagulation  param-
ters, were  found  to  be  in  favor  of  CCHF.  A  clinical
urvey of  CCHF  patients  took  longer  than  in  other
atients  due  to  the  longer  duration  of  symptoms
nd hospitalization.  Patients  with  epidemiolog-
cal characteristics  and  clinical  and  laboratory
ata compatible  with  CCHF  should  immediately  be
laced in  isolation  and  tested  for  CCHF.  This  will  not
nly obviate  unnecessary  testing  and  medication
ut also  prevent  public  health  threats  associated
ith CCHF.
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